December 9, 2024
Protected: Accelerate the path to clinic for your nasal product
There is no excerpt because this is a protected post.
READ MORE READ MOREDecember 9, 2024
There is no excerpt because this is a protected post.
READ MORE READ MOREApril 24, 2024
Rohit Mulik, Senior Manager: Formulation R&D, and Eric Kaneps, VP, Sales & Marketing at Renaissance Lakewood LLC, answer questions about the challenges in nasal drug delivery and outline how CDMO partnerships can help to overcome them.
READ MORE READ MORESupporting nasal product R&D and clinical manufacturing at Renaissance Learn more about the Nasal Product space and how Renaissance is making an impact.
READ MORE READ MOREOctober 19, 2022
Overview: The following case study is a collaboration with Renaissance Lakewood and Raven consulting on continuous...
READ MORE READ MOREOctober 6, 2022
A look at the interconnected role of the formulation, formulation excipients, and nasal spray...
READ MORE READ MORESeptember 20, 2022
A review of nasal spray formulation excipients and their potential for enhancing drug delivery. Test
READ MORE READ MOREAugust 22, 2022
When developing a sterile product, people often do not understand what’s required to manufacture the product....
READ MORE READ MOREAugust 1, 2022
A CDMO is a Contract Development and Manufacturing Organization that accelerates how pharmaceutical companies bring drugs and therapies to market. The drug discovery to market pipeline is filled with many challenges, partnering with a CDMO lowers the risk and capital investment associated with this multi-step, multi-year, and often multi-million-dollar process.
READ MORE READ MOREJune 11, 2021
Nasal spray devices are used to deliver both locally and systemically acting pharmaceutical products,1 and are readily available in the marketplace in unit dose and metered multi-dose formats.
READ MORE READ MORE"*" indicates required fields